5-氨基-1-(2-甲基苯基)-1H-吡唑-4-甲酰胺 | 792953-11-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 5-氨基-1-(2-甲基苯基)-1H-吡唑-4-甲酰胺
• 中文别名: 3,6-二氯-2-硝基苯酚
• 英文名称: (5-amino-1-o-tolyl-1H-pyrazole-4-carboxamide)
• 英文别名: 5-amino-1-(2-methylphenyl)-1H-pyrazole-4-carboxamide；5-Amino-1-(o-tolyl)-1H-pyrazole-4-carboxamide；5-amino-1-(2-methylphenyl)pyrazole-4-carboxamide
• CAS: 792953-11-8
• 化学式: C₁₁H₁₂N₄O
• mdl: MFCD18809683
• 分子量: 216.242
• InChiKey: QZPHTPXTFSOOGQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  86.9
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-氨基-1-(2-甲基苯基)-1H-吡唑-4-甲酰胺 、 2-吡啶乙酸乙酯 生成 1-(2-methylphenyl)-6-(2-pyridinylmethyl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one
  参考文献：
  名称：

  6-Arylmethyl-substituted pyrazolopyrimidines

  摘要：

  这项发明涉及新型的6-芳基甲基取代的吡唑吡嘧啶化合物，其制备方法以及它们用于生产用于改善感知、集中力、学习和/或记忆的药物。

  公开号：

  US20070161662A1
• 作为产物：
  描述：

  5-氨基-1-(2-甲基苯基)-1H-吡唑-4-腈 以 ice-water 为溶剂， 以90%的产率得到5-氨基-1-(2-甲基苯基)-1H-吡唑-4-甲酰胺
  参考文献：
  名称：

  6-Arylmethyl-substituted pyrazolopyrimidines

  摘要：

  这项发明涉及新型的6-芳基甲基取代的吡唑吡嘧啶化合物，其制备方法以及它们用于生产用于改善感知、集中力、学习和/或记忆的药物。

  公开号：

  US20070161662A1

文献信息

• 6-Cyclylmethyl- and 6-alkylmethyl-substituted pyrazolepyrimidines
  申请人：Hendrix Martin

  公开号：US20070105876A1

  公开（公告）日：2007-05-10

  The invention relates to novel 6-cyclylmethyl- and 6-alkylmethyl-substituted pyrazolopyrimidines, process for their preparation and their use for producing medicaments for improving perception, concentration, learning and/or memory.

  这项发明涉及新颖的6-环己甲基和6-烷基甲基取代的吡唑吡咯嘧啶化合物，其制备方法以及它们用于生产用于改善感知、集中力、学习和/或记忆的药物。
• [EN] COMBINATION THERAPY FOR TREATING MPS1<br/>[FR] POLYTHÉRAPIE POUR LE TRAITEMENT DE LA MPS1
  申请人：GAIN THERAPEUTICS SA

  公开号：WO2021156774A1

  公开（公告）日：2021-08-12

  The application is directed to compounds of formula (I) and their salts and solvates, wherein B, R1, R2, R3, R3', R4, R4', and R5 are as set forth in the specification, as well as to methods for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of, e.g., MPS1, optionally in combination with α-L-iduronidase or an analog or variant thereof, e.g., laronidase.

  该申请涉及公式(I)化合物及其盐和溶剂化合物，其中B、R1、R2、R3、R3'、R4、R4'和R5如规范中所述，以及其制备方法、含有相同化合物的药物组合物，以及用于治疗和/或预防MPS1等疾病的方法，可选地与α-L-异硫酸酶或其类似物或变体（例如，laronidase）结合使用。
• [EN] NEW COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS<br/>[FR] NOUVEAUX COMPOSÉS POUR LE TRAITEMENT DE TROUBLES DU SNC
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2011018495A1

  公开（公告）日：2011-02-17

  The invention relates to novel pyrazolopyrimidinones according to formula (I). The new compounds shall be used for the manufacture of medicaments, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. The new compounds are also for the manufacture of medicaments for the treatment of Alzheimer's disease. Further aspects of the present invention refer to a process for the manufacture of the compounds and their use for producing medicaments.

  该发明涉及根据式(I)的新型吡唑吡嘧啶酮。新化合物应用于制造药物，特别是用于治疗感知、注意力、学习或记忆缺陷相关疾病的药物。新化合物还用于制造治疗阿尔茨海默病的药物。本发明的进一步方面涉及制造这些化合物的方法以及它们用于制造药物的用途。
• NEW COMPOUNDS FOR THE TREATMENT OF CNS DISORDER
  申请人：HEINE Niklas

  公开号：US20110212960A1

  公开（公告）日：2011-09-01

  The invention relates to novel pyrazolopyrimidinones according to formula (I). The new compounds shall be used for the manufacture of medicaments, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. The new compounds are also for the manufacture of medicaments for the treatment of Alzheimer's disease. Further aspects of the present invention refer to a process for the manufacture of the compounds and their use for producing medicaments.

  该发明涉及根据式(I)的新型吡唑吡嘧啶酮。这些新化合物将用于制造药物，特别是用于治疗涉及感知、注意力、学习或记忆缺陷的药物。这些新化合物还将用于制造治疗阿尔茨海默病的药物。本发明的进一步方面涉及制造这些化合物的过程以及它们用于生产药物的用途。
• [EN] 1, 5-DIHYDRO-PYRAZOLO (3, 4-D) PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MODULATORS FOR THE TEATMENT OF CNS DISORDERS<br/>[FR] DÉRIVÉS DE 1,5-DIHYDRO-PYRAZOLO(3,4-D)PYRIMIDIN-4-ONE ET LEUR UTILISATION EN TANT QUE MODULATEURS DE PDE9A POUR LE TRAITEMENT DE TROUBLES DU SNC
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2009068617A1

  公开（公告）日：2009-06-04

  The invention relates to novel substituted pyrazolopyrimidines. Chemically, the compounds are characterised by general Formula (I): with R1 being phenyl or pyridyl, any of which is substituted with 1 to 4, preferably 1 to 3 substituents X; X independently of each other being selected from C2-C6-alky1 or Ci-C6-alkoxy, where C2-C6-alkyl and C1-C6-alkoxy are at least dihalogenated up to perhalogenated. preferably with 2 to 6 halogen substituents, and the halogen atoms being selected from the group of fluoro, chloro and bromo, preferably fluoro; R2 being phenyl or heteroaryl, where phenyl is substituted by 1 to 3 radicals and heteroaryl is optionally substituted by 1 to 3 radicals in each case independently of one another selected from the group of C1-C6-alkyI, C1-C6- alkoxy, hydroxycarbonyl, cyano, trifluoromethyl, amino, nitro, hydroxy, C1-C6- alkylamino, halogen, C6-C10-arylcarbonylamino, C1-C6-alkylcarbonylamino, C1- C6-alkylaminocarbonyl. C1-C6-alkoxycarbonyl, C6-C10-arylaminocarbonyl, heteroarylaminocarbonyl. heteroarylcarbonylamino, C1-C6-alkylsulphonyl- amino, C1-C6-alkylsulphonyl and C1-C6-alkylthio; The new compounds shall be used for the manufacture of medicaments, in particular medicaments for improving, perception, concentration, learning and/or memory in patients in need thereof.

  该发明涉及新型取代吡唑吡嘧啶化合物。从化学角度来看，这些化合物的特征由一般式（I）表示：其中R1为苯基或吡啶基，其中任一取代为1到4个，优选为1到3个取代基X；X独立地选自C2-C6-烷基或C1-C6-烷氧基，其中C2-C6-烷基和C1-C6-烷氧基至少经过二卤化至全卤化处理，最好具有2到6个卤素取代基，卤素原子选自氟、氯和溴，最好为氟；R2为苯基或杂环烷基，其中苯基取代为1到3个基团，杂环烷基可选择性地取代为1到3个基团，每种基团独立地选自C1-C6-烷基、C1-C6-烷氧基、羟基羰基、氰基、三氟甲基、氨基、硝基、羟基、C1-C6-烷基氨基、卤素、C6-C10-芳基羰胺基、C1-C6-烷基羰胺基、C1-C6-烷氨基羰基、C1-C6-烷氧羰基、C6-C10-芳基氨基羰基、杂环烷基氨基羰基、杂环烷基羰胺基、C1-C6-烷基磺酰氨基、C1-C6-烷基磺酰基和C1-C6-烷基硫基；这些新化合物可用于制备药物，特别是用于改善患者的感知、注意力、学习和/或记忆的药物。